The relationship between biologicals and innovation by Crommelin, Daan J.
JOURNAL OF EUROMED PHARMACY 
27
The price of medication: 
novel biologicals
There are no two European countries with the same –or even 
similar -health care systems. But they share one common 
denominator: in all European countries the costs for health 
care keep on rising faster than their GDP. The growing 
number of elderly people and the related extra claim to the 
system can only partly explain this cost increase. There are 
other drivers as well. Although the increasing use of generic 
drugs tends to reduce the cost of medicines, there is an 
upward pressure through the category of novel medicines, 
in particular biologicals: medicinal product made through 
recombinant DNA technology. In the list of 10 best-selling 
drugs (total sales 75 billion US$ in 2013), 7 out of 10 are 
biologicals (Table 1). All 7 sell between 5 and 10 billion US $ 
per annum. These biologicals are used to treat serious, often 
life-threatening diseases, such as cancer and diabetes. And 
the price for the annualised cost of treatment per patient 
can be as high 100,000 Euros or even higher (Table 2).
1.  Humira 6.  Rituxan/MabThera
2.  Enbrel 7.  Avastin
3.  Remicade 8.  Herceptin
4.  Advair/Seretide 9.  Crestor
5.  Lantus 10.  Abilify
Biologicals are in bold
Table 1: Number 1-10 blockbusters in 2013, From FiercePharma, March 25, 2014
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Table 2: Targeted medicines with companion diagnostics generate high revenues because they work so well for specific patient segments
Product Indication
Annualised 
cost per 
patient in US
Biomarker
Population 
testing positive 
for biomarker 
(%)
Projected sales 
(2012-2018)
Erbitux Colorectal, headand neck cancer $84,000 
EGFR+
KRAS-wt 37.5 $13.42 billion
Herceptin +
Perjeta Breast cancer $124,800 HER-2+ 25 $49.96 billion
Tarceva Non-small cell lungcancer $52, 800 EGFR+ 10-15 $10.8 billion
Xalkori Non-small cell lungcancer $115,200 ALK+ 4-7 $4.76 billion
Zelboraf Melanoma $112,800 BRAF+ 13.5 $4.25 billion 
Sources: EvaluatePharma and ThePinkSheet
Note: Projected sales are cumulative and global.
www.pwc.com/pharma2020
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To explain the high prices of biologicals, two arguments are 
being used: I) these products are very costly to produce, 
because of the complex manufacturing process including 
downstream processing, and /or II) the cost for innovative 
drug product development is high: 4.2 billion+ euros 
(period 2006-2012) for a successful product including the 
money to be recouped for the many failed drug products 
in the pipeline (‘attrition’) (PWC, 2012). And, somebody has 
to pay the bill. In the following I will demonstrate that the 
manufacturing costs argument is incorrect and that indeed 
‘big pharma’ is –for now- still profitable because of these 
highly successful biologicals. But there is more to it.
The high cost manufacturing myth
Admittedly, the production process of biologicals is 
complex. But, experience with generic/follow-on versions 
of biologicals (the term ‘biosimilar’ should not be used 
as it is restricted to EMA/FDA approved biological 
drug products) in countries such as India, China and 
Thailand teaches us that indeed the price can be reduced 
substantially, although there are questions about the 
quality of these ‘bioquestionables’ (Hakim et al., 2014). E.g., 
a follow-on version of Humira® will be sold in India at 20% 
of the originator’s price (1000 $ per injection)(Ail, 2014). 
Undela (from Gal 2014), published a list (Table 3) where the 
difference between costs of manufacturing and (whole)
sale(s) price is listed for a number of biological blockbusters. 
On an average, manufacturing costs make up 2.3% of 
the price. Therefore, the argument that these biologicals 
are expensive due to the manufacturing process is not 
convincing at all (cf. Undela, 2014; Gal 2014). In conclusion, 
manufacturing costs cannot be the reason for the high 
annual costs listed in Table 2.
The high margins are not specific for novel biological 
medicines. For some novel small molecule medicines 
similar situations are encountered. The new anti-hepatitis C 
medicine Sofosbuvir is sold (wholesale price) for US$ 84,000 
for a 12 weeks of treatment course used for genotypes 1 
and 2 (about US$ 1,000 per pill) and US$ 168,000 for the 
24 weeks course used for genotype 3. But the costs for 
manufacturing are close to 150 US$/course (Wikipedia). 
Interestingly, the innovator company (Gilead) will sell the 
drug for much lower prices in developing countries, e.g. for 
300 US$ per course in India (http://en.wikipedia.org/wiki/
Sofosbuvir). 
Table 3: Difference between cost of manufacture and price
Product Price (US$) Price/g (US$) Manufacturing cost * (US$/g)
Cost/price 
difference
Avastin
(bevacizumab) 687.5/100mg 6875 188 2.7%
Enbrel (etanercept) 243/25mg 9706 428 4.4%
Humira
(adalizumab) 1816/40mg 45400 308 0.7%
Rituxan (rituximab) 675/100mg 6751 188 2.8%
Herceptin
(trastuzumab) 3331/440mg 7570 126 1.7%
Erbitux (cetuximab) 600/100mg 6000 188 3.1%
Soliris (eculizumab) 5122/300mg 17073 135 0.8%
Remicade (infliximab) 784/100mg 7839 188 2.4%
Average 12877 231 2.3%
*Assuming 2g/L yield
International Journal of Medical and Pharmaceutical Sciences (IJMPS) Vol 1 issue 7, 2012 taken from Gal 2014
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Are the biological blockbusters 
saving ‘big pharma’ and is the 
current system sustainable?
The second argument to explain the exceptionally high 
prices (Table 2) is the sustainability of the current ‘big 
pharma’ business model. Many analyses have been 
published that investigated the costs for the development 
of new medicines. The PWC report uses a simple calculation 
(PWC 2012). Between 2002 and 2011 pharma industry spent 
1.1 trillion US$ on R&D for the 308 NME (new molecular 
entities) introduced as medicines in that period. And voila, 
the average cost per NME over that 10 year time frame is 3.6 
billion US$. The questions can be raised: 1) How to recoup 
these enormous amounts of money and in particular 
recoup from whom? And 2) Why is drug development 
such an expensive activity? Is the present business model 
sustainable?
The research and development investment has to be 
recouped before the patent expires or within the period 
of ‘data exclusivity and market protection’ (cf. EMA 2013). 
At present, the main source of payment for innovative 
medicines are the Western world health care systems, in 
particular in the USA where the prices as listed in Table 2 
are being paid. 
But, there is a growing concern about the sustainability of 
this business model with the Western world taking most 
of the costs of the innovation. Many wonder whether the 
innovation cost burden should be spread more evenly 
around the world and include emerging economies. 
The second question was (re 2): Why is drug development 
such an expensive activity? Is the present paradigm 
sustainable? To answer that question, excellent analyses 
and recommendations have been published. The PWC 2020 
report and the article by Munos, 2009, are mainly dealing 
with the industry perspective. Eichler et al. 2008 and 2013, 
are discussing the regulatory position regarding conditional 
and accelerated approval, the ’risk of risk avoidance’ (type II 
errors) and patient advocacy. What is the big challenge now? 
All stakeholders in the drug development process (industry, 
academia, regulatory bodies, patient organizations and 
political parties) should sit together, critically (re)consider 
their positions and hammer out a new –global- paradigm 
for drug development. This could include, e.g. spending 
less money in clinical phases, in particular phase II/III. That 
means reduce attrition in a late phase of the development 
process (‘kill’ candidate medicines in an early stage) and 
further strengthen the science base for the regulatory 
system, e.g. avoid the ‘precautionary principle’ mind set and 
continue to work on new, globally harmonized, approval 
procedures understood and supported by all stakeholders 
throughout the whole world. These measures should lead 
to an efficient, economically sustainable and fair system 
to bring highly needed NMEs to the patient. A formidable 
task, but a lot of preparatory work has already been done 
and there is no time to lose!
We need innovation in the pharmaceutical world. Just read 
the challenges and desired/required new medication listed 
in the WHO Report on Priority Medicines 2013 (Kaplan et al., 
2013). And we, the stakeholders, all have to contribute ideas 
and commit to make the new, sustainable system work. 
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